Noven Once-Daily Lithium For Bipolar Disorder Set Back Following Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to discuss data with FDA before determining a path forward for the drug after it failed to show a statistically significant efficacy benefit.
You may also be interested in...
Noven Gains Phase III Vasomotor Symptoms Candidate With JDS Acquisition
Miami firm predicts four potential new product launches in four years based on specialty pharma JDS’ pipeline.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.